GSK drug helps ovarian cancer patients live longer in latestage study

GSK drug helps ovarian cancer patients live longer in late-stage study

03:55 EDT 15 Jul 2019 | Reuters

GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday.

Original Article: GSK drug helps ovarian cancer patients live longer in late-stage study

More From BioPortfolio on "GSK drug helps ovarian cancer patients live longer in late-stage study"